Deutsche Bank Ag\ Eagle Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 48,800 shares of EGRX stock, worth $24,400. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,800

Previous 48,800 -0.0%

Holding current value

$24,400

Previous $273,000 33.7%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.63 - $15.21 $199,539 - $655,505	43,097 Added 755.69%	48,800 $255,000
Q3 2023 Nov 09, 2023	SELL	$15.21 - $22.88 $742,795 - $1.12 Million	-48,836 Reduced 89.54%	5,703 $89,000
Q2 2023 Aug 14, 2023	BUY	$17.74 - $31.87 $848,947 - $1.53 Million	47,855 Added 715.96%	54,539 $1.06 Million
Q1 2023 May 15, 2023	BUY	$25.06 - $34.09 $47,889 - $65,145	1,911 Added 40.04%	6,684 $189,000
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $2,223 - $3,539	89 Added 1.9%	4,773 $139,000
Q3 2022 Nov 14, 2022	SELL	$26.42 - $47.12 $18,203 - $32,465	-689 Reduced 12.82%	4,684 $123,000
Q2 2022 Aug 11, 2022	SELL	$41.26 - $51.35 $51,451 - $64,033	-1,247 Reduced 18.84%	5,373 $239,000
Q1 2022 May 13, 2022	SELL	$44.58 - $52.6 $32,989 - $38,924	-740 Reduced 10.05%	6,620 $328,000
Q4 2021 Feb 11, 2022	BUY	$45.82 - $56.9 $19,610 - $24,353	428 Added 6.17%	7,360 $375,000
Q3 2021 Nov 04, 2021	SELL	$43.79 - $55.78 $117,532 - $149,713	-2,684 Reduced 27.91%	6,932 $387,000
Q2 2021 Aug 11, 2021	BUY	$36.86 - $44.5 $27,866 - $33,642	756 Added 8.53%	9,616 $412,000
Q1 2021 May 13, 2021	SELL	$40.32 - $50.97 $25,320 - $32,009	-628 Reduced 6.62%	8,860 $369,000
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $55,612 - $68,436	1,333 Added 16.35%	9,488 $442,000
Q3 2020 Nov 12, 2020	SELL	$37.02 - $51.28 $2,295 - $3,179	-62 Reduced 0.75%	8,155 $347,000
Q2 2020 Aug 13, 2020	SELL	$43.24 - $55.02 $107,062 - $136,229	-2,476 Reduced 23.16%	8,217 $394,000
Q1 2020 May 14, 2020	SELL	$34.37 - $60.07 $252,688 - $441,634	-7,352 Reduced 40.74%	10,693 $492,000
Q4 2019 Feb 14, 2020	BUY	$54.32 - $64.31 $71,376 - $84,503	1,314 Added 7.85%	18,045 $1.08 Million
Q3 2019 Nov 14, 2019	BUY	$53.25 - $59.98 $80,407 - $90,569	1,510 Added 9.92%	16,731 $945,000
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $131,580 - $165,004	2,823 Added 22.77%	15,221 $845,000
Q1 2019 May 15, 2019	SELL	$38.66 - $51.82 $100,631 - $134,887	-2,603 Reduced 17.35%	12,398 $624,000
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $2.06 Million - $3.8 Million	-56,099 Reduced 78.9%	15,001 $602,000
Q3 2018 Dec 21, 2021	BUY	$66.65 - $83.86 $3.24 Million - $4.07 Million	48,568 Added 215.55%	71,100 $4.93 Million
Q3 2018 Nov 14, 2018	SELL	$66.65 - $83.86 $1.13 Million - $1.42 Million	-16,937 Reduced 42.91%	22,532 $1.56 Million
Q2 2018 Apr 21, 2020	BUY	$51.25 - $76.62 $1 Million - $1.5 Million	19,576 Added 98.41%	39,469 $2.99 Million
Q2 2018 Aug 14, 2018	SELL	$51.25 - $76.62 $2.48 Million - $3.71 Million	-48,363 Reduced 70.86%	19,893 $1.51 Million
Q1 2018 Oct 18, 2019	BUY	$52.16 - $66.86 $2.97 Million - $3.81 Million	56,992 Added 505.97%	68,256 $3.6 Million
Q1 2018 May 15, 2018	SELL	$52.16 - $66.86 $498,232 - $638,646	-9,552 Reduced 45.89%	11,264 $592,000
Q4 2017 Feb 14, 2018	SELL	$49.6 - $60.87 $4.41 Million - $5.42 Million	-88,984 Reduced 81.04%	20,816 $1.11 Million
Q3 2017 Nov 14, 2017	BUY	$46.62 - $60.36 $5.12 Million - $6.63 Million	109,800	109,800 $6.55 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $6.51M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account